Tandem Diabetes (NASDAQ: TNDM) reported Q4 EPS of ($0.48), $0.17 better than the analyst estimate of ($0.65). Revenue for the quarter came in at $28.91 million versus the consensus estimate of $22.75 million.

GUIDANCE:

Tandem Diabetes sees FY2017 revenue of $100-107 million, versus the consensus of $103.7 million.

For earnings history and earnings-related data on Tandem Diabetes (TNDM) click here.